Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry
HIV Medicine · 2026
DOI: 10.1111/hiv.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von William R Short und 7 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Rilpivirine, Pregnancy Outcome, Pregnancy Complications, Infectious, HIV Infections. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
Introduction
The Antiretroviral Pregnancy Registry (APR) is designed to detect major teratogenic effects of antiretroviral medications; other pregnancy outcomes are also recorded when reported. We compared available pregnancy and birth outcomes of women exposed to oral rilpivirine‐containing regimens (oral‐RPV cohort) versus non‐rilpivirine regimens (non‐RPV cohort) over the period 2011 to 2023.
Methods
Maternal age‐adjusted prevalence ratio (aPR) of pregnancy and birth outcomes was compared for prospectively reported pregnancies; aPR of birth defects was compared between first‐trimester exposures and combined second/third‐trimester exposures.
Results
In total, 6937 pregnancies were recorded, including 4617 (oral‐RPV cohort, 781 [16.9%]; non‐RPV cohort, 3836 [83.1%]) from the United States. Among live births, the prevalence of birth defects was lower in the oral‐RPV cohort (1.6% versus 3.8%; aPR: 0.4 [95% confidence interval (CI): 0.2–0.8]). The prevalence of birth defects in the first‐trimester oral‐RPV exposure versus second/third‐trimester exposure did not differ (aPR: 3.4 [95% CI: 0.4–26.3]). The aPR of induced abortions (1.1 [0.6–1.9]), stillbirths (0.6 [0.2–1.6]) and premature birth (0.8 [0.7–1.1]) were similar between cohorts. Prevalences for spontaneous abortion were 5.8% (oral‐RPV cohort) versus 3.2% (non‐RPV cohort) below the expected background rate (15%–20%). Low birth weights were less reported in oral‐RPV, while very low birth weights were similar between cohorts.
Conclusions
Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral‐RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non‐teratogenic effects should be interpreted with caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Johnson & Johnson, Beerse, Belgium.
- Johnson & Johnson, Titusville, New Jersey, USA.
- Syneos Health, Morrisville, North Carolina, USA.
- Johnson & Johnson, Raritan, New Jersey, USA.
ORCID-Profile: Corinne Willame, Ping Xu
Förderung
- Johnson and Johnson
Zitieren
APA
Short, W. R., Willame, C., Nguyen, H., Zhang, B., Xu, P., Birmingham, E., Van Solingen-Ristea, R., & Baugh, B. (2026). Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry. HIV Medicine. https://doi.org/10.1111/hiv.70112
Vancouver
Short WR, Willame C, Nguyen H, Zhang B, Xu P, Birmingham E, et al. Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry. HIV Medicine. 2026. doi:10.1111/hiv.70112
BibTeX
@article{Short2026,
author = {Short, William R and Willame, Corinne and Nguyen, Henry and Zhang, Bohui and Xu, Ping and Birmingham, Eileen and Van Solingen-Ristea, Rodica and Baugh, Bryan},
title = {Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70112}
}
EUVIMED